ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?
作者信息
Witteles Ronald M, Reddy Sunil A
机构信息
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Division of Oncology, Stanford University School of Medicine, Stanford, California, USA.
出版信息
JACC CardioOncol. 2022 Dec 6;5(1):133-136. doi: 10.1016/j.jaccao.2022.10.008. eCollection 2023 Feb.
Abstract
摘要
相似文献
1
ESC Cardio-Oncology Guidelines: A Triumph-But Are We Overscreening?
JACC CardioOncol. 2022 Dec 6;5(1):133-136. doi: 10.1016/j.jaccao.2022.10.008. eCollection 2023 Feb.
2
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Eur J Heart Fail. 2020 Sep;22(9):1504-1524. doi: 10.1002/ejhf.1957. Epub 2020 Aug 21.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.
5
Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology.
JACC CardioOncol. 2019 Dec 17;1(2):256-272. doi: 10.1016/j.jaccao.2019.11.007. eCollection 2019 Dec.
6
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Eur J Heart Fail. 2020 Nov;22(11):1966-1983. doi: 10.1002/ejhf.2017. Epub 2020 Oct 20.
7
Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey.
Front Cardiovasc Med. 2021 Jun 16;8:677544. doi: 10.3389/fcvm.2021.677544. eCollection 2021.
8
[2022 ESC guidelines on cardio-oncology : Understanding and treating cardiovascular side effects from cancer therapy].
Herz. 2023 Feb;48(1):15-22. doi: 10.1007/s00059-022-05149-z. Epub 2022 Nov 28.
9
The ESC Cardio-Oncology Guidelines: A Roadmap for Clinical Practice and Generating Needed Evidence.
JACC CardioOncol. 2022 Dec 6;5(1):141-144. doi: 10.1016/j.jaccao.2022.10.010. eCollection 2023 Feb.
10
Cardio-oncology: an ongoing evolution.
Future Oncol. 2015;11(14):2059-66. doi: 10.2217/fon.15.89.
引用本文的文献
1
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.
JACC CardioOncol. 2025 Apr;7(3):191-202. doi: 10.1016/j.jaccao.2024.11.003. Epub 2025 Jan 7.
2
Applications, challenges and future directions of artificial intelligence in cardio-oncology.
Eur J Clin Invest. 2025 Apr;55 Suppl 1(Suppl 1):e14370. doi: 10.1111/eci.14370.
3
Macrotroponin interference and association with cardiotoxicity in patients receiving cardiotoxic breast cancer therapy: a pilot study.
Cardiooncology. 2025 Feb 14;11(1):18. doi: 10.1186/s40959-025-00314-9.
4
Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
JACC CardioOncol. 2024 Sep 24;6(5):631-654. doi: 10.1016/j.jaccao.2024.07.017. eCollection 2024 Oct.
5
PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology.
Hearts (Basel). 2024 Sep;5(3):375-388. doi: 10.3390/hearts5030027. Epub 2024 Sep 3.
6
Cardiology and oncology: a meeting of giants.
Rev Assoc Med Bras (1992). 2024 Jun 7;70(suppl 1):e2024S114. doi: 10.1590/1806-9282.2024S114. eCollection 2024.
7
Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions.
J Am Heart Assoc. 2023 Nov 7;12(21):e029574. doi: 10.1161/JAHA.123.029574. Epub 2023 Oct 27.
本文引用的文献
1
Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment.
NEJM Evid. 2022 Sep;1(9). doi: 10.1056/evidoa2200097. Epub 2022 Aug 18.
2
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
3
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.
4
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
JACC CardioOncol. 2021 Mar;3(1):137-139. doi: 10.1016/j.jaccao.2021.01.004. Epub 2021 Mar 16.
5
Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
Eur J Cancer. 2020 Feb;126:65-73. doi: 10.1016/j.ejca.2019.11.023. Epub 2020 Jan 7.
6
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868. doi: 10.1016/j.jacc.2019.03.495.
7
Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
J Clin Oncol. 2017 Mar 10;35(8):870-877. doi: 10.1200/JCO.2016.68.7830. Epub 2016 Nov 28.
8
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
9
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis.
PLoS One. 2014 Jan 29;9(1):e87671. doi: 10.1371/journal.pone.0087671. eCollection 2014.
10
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
Zotero 插件